Chemical Patent Strategy

Definition

• A Markush group is a claim format that defines a chemical compound by a core structure with variable groups listed as alternatives
• The claim covers all compounds within the defined structural framework

Origin

• Developed in Ex parte Markush (USPTO 1924)
• Now standard worldwide

Format

• 'A compound of formula R-CO-NR1R2, wherein R is selected from the group consisting of methyl, ethyl, propyl, and phenyl
• R1 is selected from the group consisting of hydrogen and C1-C4 alkyl
• And R2 is...'

Breadth

• A single Markush claim can potentially cover millions (or billions) of specific compounds
• The claim covers every compound defined by any combination of the listed variables

Prior Art Scope

• A Markush claim is anticipated by prior art if: a single prior art compound falls within the claim (every combination is covered; if one prior art compound is within the formula, the claim is anticipated for that species)
• For obviousness, if the prior art discloses a closely related compound, the specific compound within the claim may be obvious

Written Description for Markush Claims

• The specification must describe the claimed Markush group with adequate written description
• Representative species spanning the genus
• Working examples showing that the compounds as a class have the claimed utility
• Structural similarity linking all Markush members

Enablement

• The POSITA must be able to make and use all claimed compounds without undue experimentation
• For large Markush groups, some examples must be worked

How to Structure a Markush Claim Hierarchy

• Claim 1: broadest Markush genus (all possible substituents within the structural class)
• Dependent Claims 2-10: progressively narrower Markush subgroups
• Claim 11: narrowest — the specific lead compound most likely to be commercially developed
• This hierarchy ensures fallback protection even if the broadest claims are narrowed in prosecution or invalidated.

Example

• Prior art discloses 'compounds of formula X where R is any alkyl group'
• The inventor selects R = n-butyl and discovers this specific compound has unexpectedly superior binding affinity, stability, or safety compared to other alkyl variants
• The selection of n-butyl is patentable if the advantage is truly unexpected and substantial

Requirements

• (1) the selected subset must not be individually disclosed in the prior art (if the prior art specifically described n-butyl, no selection invention)
• (2) the subset must have unexpected properties that would not be predictable from the prior art genus
• (3) the advantages must be described in the patent application and preferably supported by comparative data

Comparative Data

• Selection inventions are supported by comparative examples showing that the selected subset performs significantly better than other members of the genus
• Courts and patent offices require the comparative data to show that the advantage is: not obvious from the genus disclosure
• Genuinely surprising (not merely incremental)
• Attributable to the structural selection made

Interplay with Obvious to Try

• KSR (S.Ct. 2007) 'obvious to try' analysis is applied to chemical selection inventions
• If the prior art teaches that compounds in the genus have a range of properties and routine optimization would lead to the selected subset, the selection may be obvious
• Unexpected results are the key secondary consideration

Pharmaceutical Relevance

• Selection inventions are common in pharmaceutical patent strategy for enantiomers (active vs. inactive stereoisomers)
• Specific polymorphs
• Specific salt forms.

Composition-of-matter Claims

• Cover the chemical compound itself regardless of how it is made
• The broadest protection
• Cannot be designed around by using a different synthesis route

Process Claims

• Cover a specific method of making the compound
• Can be designed around by using a different synthesis route to make the same compound

When Process Patents Are Valuable

• When composition claims are unavailable (compound is in the prior art but the process is novel and non-obvious)
• When the process provides substantial cost or quality advantages
• When the process enables large-scale manufacturing not previously possible
• For natural products: you cannot patent a naturally occurring compound but you can patent a synthetic process to make it

Product-by-process Claims

• 'a compound made by the process of reacting A with B at 100°C for 2 hours'
• This claim covers the compound as made by this specific process

Important Limitation

• If the same compound can be made by a different process, a product-by-process claim does NOT cover the compound made by the alternative process (Atlantic Thermoplastics v. Faytex Corp.)
• The compound itself must be novel — a product-by-process claim is invalid if the compound was known before, even if the process is new

Process Patent Infringement

• More difficult to detect and prove than composition infringement
• Products in the US market: a product made abroad by a patented process can be imported, but the process patent owner can obtain exclusion at the ITC (§ 337)
• 35 U.S.C. § 271(g): importing or selling a product made abroad by a patented process infringes

Stereoisomers — Enantiomers

• Many pharmaceutical compounds have a chiral center (asymmetric carbon)
• The two mirror-image forms (enantiomers: R and S; or (+) and (-)) may have different biological activity

Example

• Lexapro (escitalopram) was patented as the active (S)-enantiomer of Celexa (citalopram; racemic)
• The enantiomer was novel over the racemate and had advantages in tolerability

Diastereomers and Other Isomers

• Geometric isomers (cis/trans)
• Structural isomers
• These can each be independently patented if they have novel and non-obvious properties

Patentability of Polymorphs

• A new polymorph of a known compound is patentable if it is novel and non-obvious
• The new polymorph typically must have an unexpected or advantageous property: better solubility
• Better bioavailability
• Higher stability
• Easier manufacturability
• Different melting point (easier processing)

Evidence of Unexpected Properties

• Provide comparative data showing the polymorph's advantages
• Data must be in the application or submitted during prosecution

Strategic Importance for Pharmaceuticals

• Manufacturers use enantiomer and polymorph patents as 'evergreening' strategies to extend effective exclusivity beyond the original compound patent
• These are legitimate patents as long as the advantages are genuine and non-obvious
• ANHYDROUS vs.

Hydrate

• Another source of polymorph-like patents
• Salt forms: different acid addition salts of a basic drug compound each have different physical properties and may be separately patentable.

Layer 1 — Composition Claims (Broadest)

• Markush group claim covering the entire structural class of compounds
• All reasonable substituents
• All reasonable combinations
• This is the core patent that competitors must design around

Layer 2 — Sub-genus Claims

• Narrower Markush groups focusing on the most commercially important subclass
• The preferred substituents
• The subgenera with the best properties

Layer 3 — Specific Compound Claims

• Individual compound claims for the lead compound(s) being commercialized
• These are easiest to enforce and most directly protect the product

Layer 4 — Process Claims

• Synthesis routes for the key compounds
• Specific conditions (temperature; pressure; catalysts; solvents) that provide commercial advantages
• These protect the manufacturing know-how

Layer 5 — Formulation Claims

• Specific formulations (excipients; delivery systems; concentrations) that provide product performance advantages
• Harder to design around than the compound itself for competitors who want to copy the product

Layer 6 — Use Claims

• Specific applications of the compound
• Method-of-use patents covering the specific application being commercialized
• Important for pharmaceuticals (indication-specific protection) and specialty chemicals (specific industrial use)

Filing Strategy

• File broad Markush genus claim first with all variants
• File provisional with all available data
• Identify lead compounds early
• File continuation applications as new data becomes available
• Add new examples to continuations (within the original disclosure)

Freedom to Operate

• For new chemical series, conduct FTO on: existing Markush claims in the same chemical space
• Process patents for synthesis routes
• Formulation patents in the relevant field